Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
Affiliation
St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland, victor.voon@gmail.com.Issue Date
2014-03MeSH
Administration, OralAtrioventricular Block
Female
Humans
Immunosuppressive Agents
Multiple Sclerosis, Relapsing-Remitting
Propylene Glycols
Sphingosine
Young Adult
Metadata
Show full item recordCitation
Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism. 2014, 70 (3):373-5 Eur. J. Clin. Pharmacol.Journal
European journal of clinical pharmacologyDOI
10.1007/s00228-013-1620-7PubMed ID
24309839Item Type
ArticleLanguage
enISSN
1432-1041ae974a485f413a2113503eed53cd6c53
10.1007/s00228-013-1620-7
Scopus Count
Collections
Related articles
- Vagomimetic effects of fingolimod: physiology and clinical implications.
- Authors: Vanoli E, Pentimalli F, Botto G
- Issue date: 2014 Jun
- Rebound of disease activity during pregnancy after withdrawal of fingolimod.
- Authors: Sempere AP, Berenguer-Ruiz L, Feliu-Rey E
- Issue date: 2013 Aug
- Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
- Authors: Gold R, Comi G, Palace J, Siever A, Gottschalk R, Bijarnia M, von Rosenstiel P, Tomic D, Kappos L, FIRST Study Investigators
- Issue date: 2014 Feb
- Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
- Authors: Castrop F, Kowarik MC, Albrecht H, Krause M, Haslinger B, Zimmer C, Berthele A, Hemmer B
- Issue date: 2012 Mar 20
- A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
- Authors: Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group
- Issue date: 2010 Feb 4